Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Coagulation01:09

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Coagulation01:06

Coagulation

Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
Introduction to Hemostasis01:05

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Individualized anticoagulation monitoring in critically ill patients: study protocol for a prospective observational comparison of Anti-Xa, viscoelastic testing, and thrombin generation.

Frontiers in medicine·2026
Same author

Comparing Hemostatic Efficacy of Four-factor Prothrombin Complex Concentrate with Andexanet Alfa in an Apixaban-treated Polytrauma Male Porcine Model.

Anesthesiology·2026
Same author

Viscoelastic point-of-care testing for monitoring unfractionated heparin in critically ill patients: a prospective observational study comparing ClotPro® IN/HI-Test, aPTT and Anti-Xa activity.

BMC anesthesiology·2026
Same author

Perioperative on-demand reversal with andexanet alfa: monitoring reversal and timing of re-anticoagulation.

British journal of anaesthesia·2025
Same author

Diagnostics and management of direct oral anticoagulants-induced bleeding.

Current opinion in anaesthesiology·2025
Same author

Hemostasis and Gingival Healing-Polyurethane Adhesive Postextraction Under Rivaroxaban Therapy in a Rodent Model.

International journal of dentistry·2025
Same journal

Generative artificial intelligence for outcome prediction in critical care: the future is now?

Current opinion in critical care·2026
Same journal

Feeding under support in critical care illness: metabolic and nutritional management during extracorporeal membrane oxygenation and continuous renal replacement therapy.

Current opinion in critical care·2026
Same journal

Multinational collaborations in critical care research: feasible and useful?

Current opinion in critical care·2026
Same journal

Personalized protein delivery in critical care: from phenotyping and endotyping to post-ICU recovery.

Current opinion in critical care·2026
Same journal

The leaky gut and microbiome in critical illness: emerging insights into microbial "translocation".

Current opinion in critical care·2026
Same journal

Parenteral nutrition and supplemental parenteral nutrition: should we use more?

Current opinion in critical care·2026
See all related articles

Related Experiment Video

Updated: May 17, 2026

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

Coagulation management.

Oliver Grottke1

  • 1Department of Anesthesiology, RWTH Aachen University Hospital, Aachen, North Rhine-Westphalia, Germany. ogrottke@ukaachen.de

Current Opinion in Critical Care
|October 24, 2012
PubMed
Summary
This summary is machine-generated.

Trauma-induced coagulopathy management is shifting towards targeted therapies like tranexamic acid and factor concentrates. While showing promise in reducing blood loss, more data is needed to fully support this evolving transfusion strategy.

Related Experiment Videos

Last Updated: May 17, 2026

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

Area of Science:

  • Trauma resuscitation
  • Hematology
  • Critical care medicine

Background:

  • Trauma-induced coagulopathy is a common complication in severely injured patients.
  • Traditional treatment with fresh frozen plasma is being replaced by targeted therapies.
  • This shift involves using coagulation factor concentrates and other hemostatic agents.

Purpose of the Study:

  • To review emerging therapeutic options for trauma-induced coagulopathy.
  • To discuss controversial topics in the management of coagulopathy.
  • To highlight the transition from empirical to targeted transfusion strategies.

Main Methods:

  • Review of multicenter trials, retrospective studies, and experimental research.
  • Analysis of the efficacy of tranexamic acid, fibrinogen concentrate, and thrombin generators.
  • Evaluation of the risks associated with prothrombin complex concentrate use.

Main Results:

  • Early tranexamic acid administration effectively reduces blood loss.
  • Coagulation factor concentrates decrease blood loss and may reduce allogeneic blood transfusions.
  • Early fibrinogen concentrate and thrombin generator use positively impacts hemostasis.
  • Prothrombin complex concentrate use carries a risk of serious adverse events.

Conclusions:

  • Coagulation factor concentrates and hemostatic agents show potential in correcting trauma-induced coagulopathy.
  • Current evidence supports a shift towards targeted transfusion strategies.
  • Further research is needed to substantiate the benefits of these agents in trauma resuscitation.